This study investigates advanced solid tumors. It evaluates the infusion of specific immune cells known as invariant Natural Killer T (iNKT) cells and PD-1+CD8+T cells.
The focus is on assessing the safety and effectiveness of this immunotherapy approach. The study evaluates how these infused cells might impact tumor burden and patient survival.
- Who can participate: Participants must have advanced lung, gastric, pancreatic, or colorectal cancer, or hepatocellular carcinoma. Eligible participants should have specific laboratory values within normal ranges and must be able to provide informed consent.
- Study details: Participants will receive an infusion of iNKT cells and CD8+T cells. An inactive substance, known as a placebo, may be used for comparison.
How understandable was the trial content above?
Hard to understand
Easy to understand